Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2348484
Max Phase: Preclinical
Molecular Formula: C24H46N2O6
Molecular Weight: 458.64
Molecule Type: Small molecule
Associated Items:
ID: ALA2348484
Max Phase: Preclinical
Molecular Formula: C24H46N2O6
Molecular Weight: 458.64
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC1CCCCC1N(CCCCCCN1C[C@H](O)[C@@H](O)[C@H](O)[C@H]1CO)C(=O)OC(C)(C)C
Standard InChI: InChI=1S/C24H46N2O6/c1-17-11-7-8-12-18(17)26(23(31)32-24(2,3)4)14-10-6-5-9-13-25-15-20(28)22(30)21(29)19(25)16-27/h17-22,27-30H,5-16H2,1-4H3/t17?,18?,19-,20+,21-,22-/m1/s1
Standard InChI Key: CSBWMHOCLXBLJJ-LMTUPJBHSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 458.64 | Molecular Weight (Monoisotopic): 458.3356 | AlogP: 2.12 | #Rotatable Bonds: 9 |
Polar Surface Area: 113.70 | Molecular Species: NEUTRAL | HBA: 7 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.90 | CX Basic pKa: 8.37 | CX LogP: 2.05 | CX LogD: 1.04 |
Aromatic Rings: 0 | Heavy Atoms: 32 | QED Weighted: 0.39 | Np Likeness Score: 0.12 |
1. Du Y, Ye H, Gill T, Wang L, Guo F, Cuconati A, Guo JT, Block TM, Chang J, Xu X.. (2013) N-Alkyldeoxynojirimycin derivatives with novel terminal tertiary amide substitution for treatment of bovine viral diarrhea virus (BVDV), Dengue, and Tacaribe virus infections., 23 (7): [PMID:23453839] [10.1016/j.bmcl.2013.01.108] |
Source(1):